ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer
Colorectal Cancer Case Studies

Tanios Bekaii-Saab, MD: Experience With Patients on Bevacizumab Plus Chemotherapy

Tanios Bekaii-Saab, MD
Published Online:Apr 26, 2016
Case 1 examines a 68-year-old man was diagnosed with advanced, unresectable colon cancer has just started treatment with FOLFIRI plus bevacizumab.

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2


What is your experience with patients who receive bevacizumab plus a CT regimen? What types of issues/side effects do they report with treatment?

Bevacizumab is relatively safe to administer with chemotherapy. It doesn't seem to exacerbate or worsen the chemotherapy toxicities. It has its toxicities, like we said with hypertension, proteinuria, arterial thromboembolic events which are rare if you choose the right patients, and issues with bowel perforation which is also a rare event. Overall, adding bevacizumab to chemotherapy seems to be fairly safe as long as you select the right patients and you are careful about stopping the bevacizumab 4 to 6 weeks prior to surgical resection, and then starting again 4 to 6 weeks after surgery.

As long as you follow those rules, overall adding bevacizumab to chemotherapy doesn't seem to exacerbate significantly the issues or the toxicities of the chemotherapy.

Unresectable Colon Cancer: Case 1

68-year-old man was diagnosed with advanced, unresectable colon cancer has just started treatment with FOLFIRI plus bevacizumab.

Publications
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.